Citadel Advisors’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Citadel Advisors’s Portfolio QNTM Stock Details QNTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76.6K	Hold	15,863	–	–	﹤0.01%	12205
2025 Q4	$116K	Buy	+15,863	New	+$173K	﹤0.01%	11522
2024 Q1	–	Sell	-38	Closed	-$2.08K	–	15587
2023 Q4	$2.28K	Buy	+38	New	+$2.68K	﹤0.01%	13716
2023 Q2	–	Sell	-41	Closed	-$3.52K	–	15379
2023 Q1	$4.1K	Sell	41 -300	-88%	-$25.7K	﹤0.01%	13984
2022 Q4	$17.5K	Buy	341 +65	+24%	+$3.6K	﹤0.01%	13245
2022 Q3	$15K	Sell	276 -41	-13%	-$2.41K	﹤0.01%	12165
2022 Q2	$16K	Buy	+317	New	+$19K	﹤0.01%	12479
2021 Q3	–	Sell	-1,354	Closed	-$145K	–	14811
2021 Q2	$154K	Buy	1,354 +834	+160%	+$96.7K	﹤0.01%	12479
2021 Q1	$65K	Buy	520 +55	+12%	+$7.69K	﹤0.01%	12780
2020 Q4	$47K	Buy	+465	New	+$54.9K	﹤0.01%	10584

Other funds holding QNTM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

PTP

Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

Citadel Advisors's QNTM Position: Q1 2026 in Review

Citadel Advisors held its Quantum Biopharma Class B Subordinate Voting Shares (QNTM) position steady in Q1 2026 at 15,863 shares worth $76.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12205.

Citadel Advisors first reported a position in QNTM in Q4 2020 and has held it in 10 quarters since. The position peaked at $154K in Q2 2021. 25 funds tracked by Wall St. Rank hold QNTM as of Q1 2026.

Citadel Advisors held 15,863 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $76.6K as of Q1 2026.
Citadel Advisors left its Quantum Biopharma Class B Subordinate Voting Shares share count unchanged in Q1 2026.
Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12205 holding.
Citadel Advisors first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q4 2020 and has held it in 10 quarters since.
Citadel Advisors's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $154K in Q2 2021.
25 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.